Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia

Int J Biol Macromol. 2019 Mar 1:124:1123-1131. doi: 10.1016/j.ijbiomac.2018.11.280. Epub 2018 Dec 3.

Abstract

Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. The acquired Janus kinase 2 (JAK2) K607N somatic mutation was detected in about 6.8% of acute myeloid leukemia (AML) patients. However, roles of JAK2 K607N mutation in the leukemogenesis of AML remain unclear. In this study, loss of interaction between K607 and E877 was identified as key reasons for JAK2 K607N mutation constitutive activation. JAK2 K607N and mutations (K607A, K607G and E877A) abolished the K607 and E877 interaction caused JAK2 constitutive activation. While, mutations (K607R, E877D) repairing this interaction reduced K607N mutation's activity. Furthermore, our studies showed that disruption of K607 and E877 interaction abolished JH1/JH2 domains' interactions and led to JAK2 constitutive activation. More importantly, JAK2 K607N and mutations disrupted this interaction enhanced JAK2-STAT5 pathway activation and the proliferation of Ba/F3 cells. Thus our studies provide clues in understanding the leukemogenesis of JAK2 K607N mutation in AML.

Keywords: Acute myeloid leukemia; Constitutive activation; Janus kinase 2.

MeSH terms

  • Amino Acid Substitution
  • Cell Line, Tumor
  • Humans
  • Janus Kinase 2* / genetics
  • Janus Kinase 2* / metabolism
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / metabolism
  • Leukemia, Myeloid, Acute* / pathology
  • Mutation, Missense
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism
  • Protein Domains
  • STAT5 Transcription Factor / genetics
  • STAT5 Transcription Factor / metabolism

Substances

  • Neoplasm Proteins
  • STAT5 Transcription Factor
  • JAK2 protein, human
  • Janus Kinase 2